Retinal Vein Occlusion Treatment Market Growth Trajectory Through 2024-2033

Spread the love

The Retinal Vein Occlusion Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Retinal Vein Occlusion Treatment Market:
https://www.thebusinessresearchcompany.com/report/retinal-vein-occlusion-treatment-global-market-report

According to The Business Research Company’s Retinal Vein Occlusion Treatment Global Market Report 2024, The retinal vein occlusion treatment market size has grown strongly in recent years. It will grow from $2.11 billion in 2023 to $2.26 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to the adoption of combination therapies targeting multiple aspects of disease pathophysiology, the growing prevalence of diabetes and hypertension expanded access to healthcare services and specialized retinal care, clinical trials demonstrating the efficacy of new treatment modalities, and the development of anti-VEGF therapies.

The retinal vein occlusion treatment market size is expected to see strong growth in the next few years. It will grow to $2.97 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to cost-effectiveness and reimbursement policies, patient preferences for non-invasive treatments, increased healthcare spending globally, an increasing aging population, and the development of new drugs and therapies. Major trends in the forecast period include gene therapy advancements, nanotechnology for drug delivery, artificial intelligence (AI) in diagnostics, telemedicine and remote monitoring, and the development of patient-centric technologies.

The increasing prevalence of eye conditions is expected to propel the growth of the retinal vein occlusion treatment market going forward. Eye conditions refer to any disorders or diseases affecting the eyes or vision. They can include a range of issues, from minor irritations and infections to more serious conditions like glaucoma, cataracts, macular degeneration, and diabetic retinopathy. The rise in cases of eye conditions is attributed to factors such as aging populations and the increasing prevalence of diabetes and hypertension. Retinal vein occlusion treatment aims to restore blood flow and reduce inflammation to prevent vision loss and manage complications associated with this eye condition. For instance, in January 2024, according to the Centers for Disease Control and Prevention, a US-based science and data-driven service organization that protects the public’s health, over 3.4 million Americans aged 40 years and older were blind or visually impaired, which is expected to double by 2030. Therefore, the increasing prevalence of eye conditions is driving the growth of the retinal vein occlusion treatment market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=18453&type=smp

The retinal vein occlusion treatment market covered in this report is segmented –

1) By Disease Type: Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO)
2) By Diagnosis: Optical Coherence Tomography, Fundoscopic Examination, Fluorescein Angiography
3) By Treatment: Anti-Vascular Endothelial Growth Factor (Anti-VEGF), Corticosteroid Drugs, Other Treatments
4) By End-user: Hospital And Clinics, Research And Academics, Other End-Users

Major companies operating in the retinal vein occlusion treatment market are focusing on developing innovative products, such as interchangeable biosimilars, to enhance treatment options and improve patient accessibility. An interchangeable biosimilar is a biologic drug that is highly similar to an existing reference biologic and can be used as an alternative to manage inflammation and fluid leakage effectively. For instance, in May 2024, Biocon Biologics Limited, an India-based biosimilar manufacturing company, received US Food and Drug Administration approval for Yesafili (aflibercept-jbvf), which is an interchangeable biosimilar of EYLEA (aflibercept). It functions as a vascular endothelial growth factor (VEGF) inhibitor, treating various ophthalmic conditions such as neovascular age-related macular degeneration (wet AMD), macular edema secondary to retinal vein occlusion (branch RVO or central RVO), diabetic macular edema (DME), and myopic choroidal neovascularization (myopic CNV).

The retinal vein occlusion treatment market report table of contents includes:

1. Executive Summary
2. Retinal Vein Occlusion Treatment Market Characteristics
3. Retinal Vein Occlusion Treatment Market Trends And Strategies
4. Retinal Vein Occlusion Treatment Market – Macro Economic Scenario
5. Global Retinal Vein Occlusion Treatment Market Size and Growth
.
.
.
32. Global Retinal Vein Occlusion Treatment Market Competitive Benchmarking
33. Global Retinal Vein Occlusion Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Retinal Vein Occlusion Treatment Market
35. Retinal Vein Occlusion Treatment Market Future Outlook and Potential Analysis
36. Appendix